Study title: Open Label, Multicenter, Phase IIIB, Follow up Study to Investigate the Antibody Response to Hepatitis B, Acellular Pertussis and Inactivated Poliovirus Antigens one Month after the 4th Hexavac® Vaccination in Healthy Children, who Participated in the NeisVac-C Non-Interference Study 216
Type of medicine: Non-centrally authorised vaccines | |||||
Therapeutic area: Virus Diseases [C02]Â | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: N. meningitidis group C polysaccharide conjugated to tetanus toxoid adsorbed on Al3+ | |||||
ATC code: J07AH | |||||
Document link: | |||||
Document date: | |||||
Study number: Study 224 | |||||
EudraCT number: | |||||
Scope of study: CLINICAL | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | - |